Alzheimer’s disease: a blood test to estimate the 5- and 10-year risk of cognitive decline
A Mayo Clinic study published on 16 November 2026 in JAMA Neurology shows that measuring the protein p-tau217 in blood, together with age, sex and genetic background, makes it possible to estimate, as a percentage, the risk that a person with no memory complaints today will develop mild cognitive impairment or dementia over the following 5 or 10 years.
Background
The brain changes typical of Alzheimer’s disease (build-up of amyloid-beta and tau protein) begin many years before symptoms appear. Today they can be detected with brain PET imaging or cerebrospinal fluid analysis, which are expensive or invasive. In recent years blood tests have spread, especially p-tau217 (tau phosphorylated at position 217), which closely reflects the presence of amyloid in the brain.
The problem is that a “positive” result in someone without symptoms says little on its own: many people with abnormal biomarkers stay cognitively intact for years. The laboratory value needs to be translated into a concrete risk over time.
The study
• Led by Alicia Algeciras-Schimnich, a laboratory medicine and pathology researcher at Mayo Clinic (Rochester, USA)
• 1,644 cognitively unimpaired people from the Mayo Clinic Study of Aging, a population-based study in Minnesota, were analysed
• Findings were confirmed in another 534 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
• Ages 60 to 90 (median 72); all had plasma p-tau217 (measured with an automated assay), APOE genotyping and repeated cognitive assessments over the years
The results
• People with high p-tau217 (90th percentile) had a roughly 2.5- to 3-fold higher risk of progression than those with low levels (10th percentile)
• At age 75, the 5-year risk of mild cognitive impairment rose from 7% with low p-tau217 to 17% with high p-tau217; the 10-year risk rose from 15% to 35%
• Age matters a great deal: at the same high p-tau217 level, the 5-year risk was 6% at age 65 and 37% at age 85; the 10-year risk was 17% and 66%, respectively
• Once p-tau217 was taken into account, the APOE ε4 variant added little to the prediction
• Similar results were obtained with the p-tau217/amyloid-beta 42 ratio
What changes for laboratory testing
The key message is about method: instead of reporting p-tau217 as “positive” or “negative”, the authors propose expressing it as a personalised absolute risk, as is already done for cardiovascular risk. This is an important step for laboratory medicine, because it makes the result meaningful for both doctor and patient.
It is worth remembering that memory decline also has reversible causes that laboratory tests help rule out, such as vitamin B12 deficiency, raised homocysteine or hypothyroidism (see the thyroid check-up). We recently covered another tau-based blood test, for chronic traumatic encephalopathy.
Who is it relevant to
• People over 65, and especially over 70, because age is the factor that changes the risk most
• Clinicians selecting participants for prevention trials of anti-amyloid drugs (such as AHEAD 3-45 and TRAILBLAZER-ALZ 3), which already use blood biomarkers
• In the future, anyone deciding whether to start preventive treatment, if and when such treatments prove effective
Limitations
• The risk estimates were developed in a Minnesota population with limited ethnic diversity and need to be validated in other populations
• Only one commercial p-tau217 assay was used: cut-offs cannot be automatically transferred to other methods
• This is an observational study: it measures an association and does not show what reduces the risk
• Current guidelines do not recommend Alzheimer’s biomarker testing in people without cognitive symptoms, partly because no preventive therapy has yet been approved
In summary
• Plasma p-tau217, combined with age, sex and APOE, can estimate the 5- and 10-year risk of cognitive impairment
• At age 75, the 10-year risk goes from 15% to 35% between low and high p-tau217 levels
• Age remains the most important factor
• It is not a screening test for healthy people: it is a research tool and, in the future, an aid to shared decisions with the doctor
Sources:
Algeciras-Schimnich A. et al., JAMA Neurology, 16 November 2026; Mayo Clinic News Network
Laboratory tests:
Vitamina B12, Omocisteina, Check-Up Tiroide, Check-Up Completo
Diseases, symptoms and related pages:
Cervello – Demenza senile precoce, Parkinson, Amiloidosi, Encefalopatia traumatica cronica (CTE): un esame del sangue per riconoscerla in vita, Lecanemab – Farmaco contro l’Alzheimer, Donanemab – Farmaco per l’Alzheimer, Vaccino contro l’herpes zoster e riduzione del rischio di demenza















































Discussion about this post